DNA topoisomerase II — Drug Target

All drugs that target DNA topoisomerase II — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

Liposomal chemotherapy; topoisomerase II inhibitor · Anthracycline chemotherapy agent (liposomal formulation) · antitumor antibiotic

Marketed (2)

• Liposome doxorubicin · Sun Yat-sen University · Liposomal chemotherapy; topoisomerase II inhibitor · Oncology
  Liposome-encapsulated doxorubicin delivers the chemotherapy agent doxorubicin to cancer cells while reducing exposure to healthy tissues, thereby improving tolerability.
• Doxorubicin hydrochloride liposome · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Anthracycline chemotherapy agent (liposomal formulation) · Oncology
  Doxorubicin hydrochloride liposome is a chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, delivered via liposomal nanoparticles to improve tumor targeting and reduce systemic toxicity.

Phase 2 pipeline (1)

• Aldoxorubicin HCl · ImmunityBio, Inc. · antitumor antibiotic · Oncology
  Aldoxorubicin HCl is a prodrug that selectively releases doxorubicin in acidic environments, such as tumor cells, to exert its cytotoxic effects.